ADME-guided design and synthesis of aryloxanyl pyrazolone derivatives to block mutant superoxide dismutase 1 (SOD1) cytotoxicity and protein aggregation: Potential application for the treatment of amyotrophic lateral sclerosis
Amyotrophic lateral sclerosis (ALS) is an orphan neurodegenerative disease currently without a cure. The arylsulfanyl pyrazolone (ASP) scaffold was one of the active scaffolds identified in a cell-based high throughput screening assay targeting mutant Cu/
Chen, Tian,Benmohamed, Radhia,Kim, Jinho,Smith, Karen,Amante, Daniel,Morimoto, Richard I.,Kirsch, Donald R.,Ferrante, Robert J.,Silverman, Richard B.
p. 515 - 527
(2012/03/26)
Substituted pyrazolones require N2 hydrogen bond donating ability to protect against cytotoxicity from protein aggregation of mutant superoxide dismutase 1
Amyotrophic lateral sclerosis (ALS) is a debilitating and fatal neurodegenerative disease. Although the cause remains unknown, misfolded protein aggregates are seen in neurons of sporadic ALS patients, and familial ALS mutations, including mutations in su
Trippier, Paul C.,Benmohammed, Radhia,Kirsch, Donald R.,Silverman, Richard B.
p. 6647 - 6650
(2013/01/14)
TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS
The present invention relates to the identification of compounds and pharmaceutical compositions thereof for treating subjects with amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The invention also provides methods of preparing the provided compounds.
-
Page/Page column 116
(2010/07/10)
More Articles about upstream products of 1226145-00-1